Antiviral effect of emodin from Rheum palmatum against coxsakievirus B₅ and human respiratory syncytial virus in vitro

Abstract

Viral infections are the major causes of morbidity and mortality in elderly people and young children throughout the world. The most common pathogens include coxsackie virus (CV) and respiratory syncytial virus (RSV). However, no antiviral agents with low toxicity and drug resistance are currently available in clinic therapy. The present study aimed to examine the antiviral activities of emodin (an ingredient of Rheum palmatum) against CVB5 and RSV infections, in an attempt to discover new antiviral agents for virus infection. The monomer emodin was extracted and isolated from Rheum palmatum. The antiviral activities of emodin on HEp-2 cells were evaluated, including virus replication inhibition, virucidal and anti-absorption effects, by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tet-razolium bromide (MTT) assay and plaque reduction assay (PRA). The kinetics of virus inhibition by emodin in a period of 14 h was further determined by plaque assay and quantitative real time PCR (qPCR). Cytokine (IFN-γ, TNF-α) mRNA expressions after emodin treatment (7.5, 15, 30 μmol/L) were also assessed by qPCR post-infection. The results showed that emodin had potent inhibitory activities against CVB5 and RSV, with the 50% effective concentration (EC₅₀) ranging from 13.06 to 14.27 μmol/L and selectivity index (SI) being 5.38–6.41 μmol/L. However, emodin couldn’t directly inactivate the viruses or block their absorption to cells. It acted as a biological synthesis inhibitor against CVB₄ and RSV in a concentration- and time-dependent manner, especially during the first 0–4 h post-infection. Moreover, emodin could decrease the mRNA expression of IFN-α but enhance TNF-γ expression significantly compared to the viral controls in vitro. Our results provide a molecular basis for development of emodin as a novel and safe antiviral agent for human enterovirus and respiratory virus infection in the clinical therapy.

References

[1] PallanschMA. Coxsackievirus B epidemiology and public health concerns. Curr Top Microbiol Immunol, 1997, 233: 13-30

[2] RamsinghAI. CVB-induced pancreatitis and alterations in gene expression. Curr Top Microbiol Immunol, 2008, 323: 241-258

[3] ChapmanNM, KimKS. Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol, 2008, 323: 275-292

[4] AntonaD, LévêqueN, ChomeJJ, et al.. Surveillance of enteroviruses in France, 2000-2004. Eur J Clin Microbiol Infect Dis, 2007, 26: 403-412

[5] TralleroG, AvellonA, OteroA, et al.. Enteroviruses in Spain over the decade 1998-2007: virological and epidemiological studies. J Clin Virol, 2010, 47: 170-176

[6] ZhongQ, YangZ, LiuY, et al.. Antiviral activity of arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol, 2009, 154(4): 601-607

[7] HanJF, JiangT, FanXL, et al.. Recombination of human coxsackievirus B5 in hand, foot, and mouth disease patients, China. Emerg Infect Dis, 2012, 18: 351-353

[8] RaviL I, LiangL, SutejoR, et al.. A systems-based approach to analyse the host response in murine lung macrophages challenged with respiratory syncytial virus. Bmc Genomics, 2013, 14(3): 339-342

[9] NairH, NokesDJ, GessnerBD, et al.. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010, 375(9725): 1545-1555

[10] HolbergCJ, WrightAL, MartinezFD, et al.. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol, 1991, 133(11): 1135-1151

[11] MacDonaldNE, HallCB, SuffinSC, et al.. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med, 1982, 307(7): 397-400

[12] Morales F, Calder MA, Inglis JM, et al. A study of respiratory infections in the elderly to assess the role of respiratory syncytial virus. J Infect,7(3):236-247

[13] RotbartHA. Treatment of picornavirus infections. Antiviral Res, 2002, 53: 83-98

[14] MurataY. Respiratory syncytial virus vaccine development. Clin Lab Med, 2009, 29: 725-739

[15] MejíasA, Chávez-BuenoS, RíosAM, et al.. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother, 2004, 48(5): 1811-1822

[16] KrilovLR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther, 2011, 9: 27-32

[17] TangT, YinLW, YangJ, et al.. Emodin, an anthraquinone derivative from Rheum officinale Baill, enhances cutaneous wound healing in rats. Eur J Pharmacol, 2007, 567: 177-185

[18] ReedLJ, MuenchHA. A simple method of estimating fifty percent endpoints. Am J Hyg, 1938, 27: 493-497

[19] ShiL, XiongH, HeJ, et al.. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol, 2007, 152: 1447-1455

[20] SongJM, LeeKH, SeongBL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res, 2005, 68(2): 66-74

[21] BoulwareSL, BronsteinJC, NordbyEC, et al.. Identification and characterization of benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res, 2001, 51: 111-125

[22] Dr SuzanneEM, RebeccaL, Dr MosesKN, et al.. Pathogenesis of Coxsackievirus-B5 acquired from intra-renal porcine islet cell xenografts in diabetic mice. Xenotransplantation, 2009, 16(2): 91-98

[23] YuanJ, YuM, LinQW, et al.. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol, 2010, 185(7): 4004-4010

[24] Robert-TissotC, RueggerVL, CattoriV, et al.. The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation. Vet Immunol Immunopathol, 2011, 143(3-4): 269-281

[25] LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001, 25: 402-408

[26] ChenYC, ShenSC, LeeWR, et al.. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol, 2002, 64(12): 1713-1724

[27] KumarA, DhawanS, AggarwalBB. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNFinduced NF-kB activation, I?B degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene, 1998, 17: 913-918

[28] HsiangCY, HoTY. Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures. Br J Pharmacol, 2008, 155: 227-235

[29] ShuangsuoD, ZhengguoZ, YunruC, et al.. Inhibition of the replication of hepatitis B virus in vitro by emodin. Med Sci Monit, 2006, 12: BR302-BR306

[30] SchwarzS, WangK, YuW, et al.. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res, 2011, 90: 64-69

[31] BattistuttaR, SarnoS D, MolinerE, et al.. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem, 2000, 275: 29618-29622

[32] SydiskisRJ, OwenDG, LohrJL, et al.. Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob Agents Chemother, 1991, 35: 2463-2466

[33] KanQ, LiD, YuZ. Specific expression of human interferon-gamma controls hepatitis B virus replication in vitro in secreting hepatitis B surface antigen hepatocytes. Virol Methods, 2012, 180(1-2): 84-90

[34] Stubblefield ParkSR, WidnessM, LevineA D, et al.. T cell-, interleukin-12-, and gamma interferon-driven viral clearance in measles virus-infected brain tissue. J Virol, 2011, 85(7): 3664-3676

[35] HenkeA, ZellR, EhrlichG, et al.. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J Virol, 2001, 75: 8187-8194

[36] OpavskyMA, PenningerJ, AitkenK, et al.. Susceptibility to myocarditis is dependent on the response of alpha/beta T lymphocytes to coxsackieviral infection. Circ Res, 1999, 85: 551-558

[37] HorwitzMS, KrahlT, FineC, et al.. Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon. J Virol, 1999, 73: 1756-1766

[38] KandaT, TakahashiaT, KudobS, et al.. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. Life Sci, 2004, 75: 1435-1447

[39] HuberSA, BornW, O’BrienR. Dual functions of murine CD cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vc¹⁺ and Vc⁴⁺ cells. Microbes Infect, 2005, 7: 537-543

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg